Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
Jimmy Ruiz, MD, reflects on his career journey in North Carolina and the transformative progress in lung cancer treatment. Early in his career, limited tools like chemotherapy presented…
David Simel, MD, and William Kim, MD, explore renal cell carcinoma in this JAMA Clinical Review podcast. They discuss key insights from the 2019 Nobel Prize research on…
Advances in non-small cell lung cancer (NSCLC) treatment have transformed care from a one-size-fits-all approach in the 1990s to highly personalized regimens today. Treatment now considers actionable mutations…
Faith Davies, MD, shares insights from the IMS 2024 session on high-risk disease, highlighting the debut of a unified high-risk definition. This new framework incorporates 17p deletions, mutations,…
Muneeb Shah MD, and Luke Maxfield, MD, break down the essentials of skin cancer, explaining the causes, symptoms, and treatments of basal cell carcinoma, squamous cell carcinoma, and…
The dialogue between Venugopal, MD, and Nabhan, MD, delves into unresolved challenges in treating chronic myeloid leukemia (CML). Venugopal emphasizes the need for targeted therapies in CML blast…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Pompe disease is a progressive, life-threatening genetic neuromuscular disorder. Late-onset Pompe disease (LOPD), affecting individuals over one year old, leads to trunk and proximal muscle weakness, often impacting…
Beth A. Vogt, MD discusses Post-infectious Glomerulonephritis (GN), often following strep infections, affects children aged 5-15. Symptoms typically emerge 7-14 days post-infection and include cola-colored urine, edema, hypertension,…
